本报道最初发表于Endpoints News。请点击这里查看原文
The White House threw its weight behind efforts to help US biotech compete with China, using the administration’s budget proposal to outline FDA policy changes to speed up trials, cut costs for companies that do experimental work in the US, and expedite regulatory reviews.
白宫大力支持帮助美国生物科技与manbetx3.0 竞争的举措,并借助政府的预算提案,提出通过调整美国食品药品监督管理局(FDA)的政策来加快临床试验、降低在美国开展实验性工作的企业成本,并加速监管审评。
您已阅读5%(398字),剩余95%(6911字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。